Ketamine For Suicidal Ideation

Summary

This study will examine the effects of Intravenous (IV) ketamine both in an outpatient population and with subjects on the inpatient unit with suicidal ideation (SI).

Timeline

Start

2012-01

Primary completion

2014-09

Completion

2014-09

Outcome

Mixed primary results

registry MEAN Ketamine: 10.8 (Standard Deviation 8.5) units on a scale MEAN Midazolam: 14.0 (Standard Deviation 10.2) units on a scale NCT01507181 ↗

registry analysis (superiority or other test); Ketamine vs Midazolam; p = 0.32; t-test, 2 sided NCT01507181 ↗

registry MEAN Ketamine: 8.8 (Standard Deviation 8.3) units on a scale MEAN Midazolam: 15.3 (Standard Deviation 10.9) units on a scale NCT01507181 ↗

registry analysis (superiority or other test); Ketamine vs Midazolam; p = 0.047; t-test, 2 sided NCT01507181 ↗

Publications

• Results Murrough JW, Soleimani L, DeWilde KE, Collins KA, Lapidus KA, Iacoviello BM, Lener M, Kautz M, Kim J, Stern JB, Price RB, Perez AM, Brallier JW, Rodriguez GJ, Goodman WK, Iosifescu DV, Charney DS. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med. 2015 Dec;45(16):3571-80. doi: 10.1017/S0033291715001506. Epub 2015 Aug 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ketamine	Small molecule	0.5 mg/kg	Intravenous
Comparator	Midazolam	Small molecule	0.45 mg/kg	Intravenous

Indications

No indication recorded.